## BAY 2965501


Cat. No.:	HY-153343				
CAS No.:	2732902-08-6				
Molecular Formula:	C <sub>20</sub> H <sub>19</sub> FN <sub>4</sub> O <sub>3</sub> S				
Molecular Weight:	414.45				
Target:	DGK				
Pathway:	Metabolic Enzyme/Protease				
Storage:	Powder	-20°C	3 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

## SOLVENT & SOLUBILITY

In Vitro	0,	DMSO : ≥ 100 mg/mL (241.28 mM) * "≥" means soluble, but saturation unknown.					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.4128 mL	12.0642 mL	24.1284 mL		
	Stock Solutions	5 mM	0.4826 mL	2.4128 mL	4.8257 mL		
		10 mM	0.2413 mL	1.2064 mL	2.4128 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					

BIOLOGICAL ACTIVITY				
Description	BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer <sup>[1]</sup> .			
IC <sub>50</sub> & Target	$DGK\zeta^{[1]}$			
In Vitro	BAY 2965501 increases natural killer cell- and T-cell-mediated tumor cell killing, and enhances IL2-induced natural killer cell activation <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	BAY-2965501 inhibits tumor growth inhibition in an F9 testicular teratoma model, and the combination of BAY-2965501 with immune checkpoint blockade results in additive or synergistic effects <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES





[1]. Schubert N, et al. Phosphorylated extracellular signal-regulated kinase (pERK) activation in T effector cells as a target engagement biomarker for the DGKζ inhibitor BAY2965501 in clinical trials. Cancer Research, 2023, 83(7\_Supplement): 2116-2116.

[2]. Rienk Offringa, et al. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy. Regular and Young Investigator Award Abstracts. Immune Cell Types and Biology.

[3]. Schlicher L, et al. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status. Front Immunol. 2023 Oct 31;14:1297175.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA